Autolus Therapeutics plc (NASDAQ:AUTL) Stake Reduced by Eversept Partners LP

Eversept Partners LP lessened its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 75.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 98,895 shares of the company's stock after selling 307,663 shares during the period. Eversept Partners LP's holdings in Autolus Therapeutics were worth $232,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Barclays PLC increased its holdings in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in Autolus Therapeutics in the fourth quarter valued at about $35,000. Arkadios Wealth Advisors acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $47,000. Daiwa Securities Group Inc. boosted its stake in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after acquiring an additional 8,479 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Autolus Therapeutics during the 4th quarter worth approximately $75,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Truist Financial cut their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Stock Down 5.0 %

Shares of AUTL traded down $0.07 during trading hours on Friday, reaching $1.33. 2,740,804 shares of the company traded hands, compared to its average volume of 1,469,451. The stock has a market capitalization of $353.91 million, a PE ratio of -1.10 and a beta of 2.06. The stock has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $2.47. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. Research analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.